REFERENCES
- Arribas JR, Pulido F, Delgado R, et al. Lopinavir/ritonavir as single drug therapy for maintenance of HIV-1 viral suppres-sion: 48-week results of a randomized, controlled, open-la-bel, proof-of-concept pilot clinical trial (OK Study). J Acquir Immune Defic Syndr 2005;40:80–287.
- Campo RE, Lalanne R, Tanner TJ, Jayaweera DT, et al. Lopi-navir/ritonavir maintenance monotherapy after successful viral suppression with standard highly active antiretroviral therapy in HIV-1-infected patients. AIDS. 2005;19:447–449.
- Pierone G Jr, Mieras J, Bulgin-Coleman D, et al. A pilot study of switch to lopinavir/ ritonavir (LPV/r) monotherapy from nonnucleoside reverse transcriptase inhibitor-based therapy. HIV Clin Trials. 2006;7:237–245.
- Swindells S, DiRienzo AG, Wilkin T, et al. Regimen simpli-fication to atazanavir-ritonavir alone as maintenance an-tiretroviral therapy after sustained virologic suppression. JAMA. 2006;296:806–814.
- Karlstrom O, Josephson F, Sonnerborg A. Early virologic rebound in a pilot trial of ritonavir-boosted. J Acauir Im-mune Defic Syndr December 7, 2006. [Epub ahead of print] Accessed January 23, 2007.
- 2006 16th International Conference on AIDS, Toronto, Can-ada; oral presentations. Available at: http://www.aids2006.org/PAG/PSession.aspx?s=256 & http://www.aids2006.org/PAG/PSession.aspx?s=263.
- Negredo E, Bonjoch A, Clotet B. Benefits and concerns of simplification strategies in HIV-infected patients. J Antimi-crob Chemother 2006;58:235–242.
- Joly V, Yeni P. Nucleoside analogue-sparing strategy for the treatment of chronic HIV infection: potential interest and clinical experience. Antivir Ther 2005;10:29–40.
- Lafeuillade A, Soles C, Halfon P, Chadapaud S, Hittinger G, Lacarelle B. Differences in the detection of three HIV-1 protease inhibitors in non-blood compartments: clinical correlations. HIV Clin Trials. 2002;3:27–35.
- Sprinz E, Neto AJ, Bergman E, et al. Substitution with lopi-navir/ritonavir improves patient-reported outcomes includ-ing quality of life in patients who were intolerant to their antiretroviral therapy. HIV Clin Trials. 2006;7:291–308.
- Vora S, Marcelin AG, Gunthard HF, et al. Clinical validation of atazanavir/ritonavir genotypic resistance score in pro-tease inhibitor-experienced patients. AIDS. 2006;2(20):35–40.
- Hicks C, King MS, Gulick RM, et al. Long-term safety and durable antiretroviral activity of lopinavir/ritonavir in treatment-naive patients: 4 year follow-up study. AIDS. 2004;26(18):775–779.
- de Mendoza C, Valer L, Bacheler L, Pattery T, Corral A, So-riano V. Prevalence of the HIV-1 protease mutation I47A in clinical practice and association with lopinavir resistance. AIDS. 2006;20: 1071–1074.
- Kagan RM, Shenderovich MD, Heseltine PN, Ramnarayan K. Structural analysis of an HIV-1 protease I47A mutant resistant to the protease inhibitor lopinavir. Protein Sci. 2005;14:1870–1878.
- Friend J, Parkin N, Liegler T, Martin JN, Deeks SG. Isolated lopinavir resistance after virological rebound of a ritonavir/ lopinavir-based regimen. AIDS. 2004;18:1965–1966.